paclitaxel

(redirected from Paxene)
Also found in: Medical, Wikipedia.

pac·li·tax·el

 (păk′lĭ-tăk′səl)
n.
An anticancer drug that was first derived from the bark of the Pacific yew tree and is used in the treatment of ovarian and breast cancer that has not responded to prior therapy.

[Pac(ific yew) + New Latin (brevifō)li(a), specific epithet of the Pacific yew (Latin brevis, short + Latin fōlium, leaf; see folium) + alteration of Taxol.]

paclitaxel

(ˌpæklɪˈtæksəl)
n
(Medicine) a drug derived from the yew tree and used to treat cancer
Translations

paclitaxel

n paclitaxel m
Mentioned in ?
References in periodicals archive ?
has received approval to market its proprietary anti-cancer drug, PAXENE (paclitaxel), in Canada for the treatment of AIDS-related Kaposi's sarcoma in patients who have failed prior liposomal anthracycline therapy.
Combino Pharm SL representatives will work closely with hospital pharmacists to ensure Paxene is included in oncology center protocols throughout Spain.
or Europe and in Europe sales of QVAR may not be spurred by the approval of QVAR in Easi-Breathe; that IVAX may not receive final approval for HFA albuterol sulfate in its breath-activated inhaler or that launch will be delayed; market acceptance and demand for IVAX' respiratory products may not be as anticipated; that CFC propellants may not be removed from the market when anticipated or at all; that IVAX may not enter into other collaborative agreements related to products in our proprietary pipeline; and that the collaboration with Mayne regarding Paxene in the European Union may not achieve the results expected.
Paxene is the equivalent of Bristol-Myers Squibb's Taxol(R), with annual European sales of $400-600 million.
As previously announced on January 23, 2004, the European Union's Committee for Proprietary Medicinal Products, the scientific committee of the European Medicines Evaluation Agency, issued a positive opinion recommending the extension of indication of the existing marketing authorization for IVAX' Paxene to include treatment of metastatic breast cancer and metastatic ovarian cancer in the European Union.
IVAX appointed Immunex to promote Paxene, its branded form of